<DOC>
	<DOCNO>NCT02959385</DOCNO>
	<brief_summary>Neoadjuvant chemoradiotherapy ( Neo-CRT ) plus surgery regard standard care patient resectable locally advanced oesophageal cancer . Many study suggest definitive Radiochemotherapy ( CRT ) similar efficacy neoadjuvant chemoradiotherapy plus surgery esophageal cancer respond chemoradiation . Herein , single center prospective randomize phase II clinical trial carry compare efficacy safety definitive radiochemotherapy versus neoadjuvant radiochemotherapy plus radical resection patient achieve clinical complete response ( CCR ) neoadjuvant radiochemotherapy stage II-III esophageal Cancer .</brief_summary>
	<brief_title>A Phase II Trial Compare Efficacy Safety CRT VS Neo-CRT Patients Who Achieved CCR Esophageal Cancer</brief_title>
	<detailed_description>1 . Compare progression-free survival ( PFS ) overall survival ( OS ) definitive radiochemotherapy versus ( VS ) neoadjuvant radiochemotherapy plus radical resection esophageal cancer patient achieve clinical complete response neoadjuvant treatment ; 2 . Compare toxic side effect definitive radiochemotherapy versus neoadjuvant radiochemotherapy plus radical resection esophageal cancer patient achieve clinical complete remission neoadjuvant treatment ; 3 . Compare relationship consistency pathological complete response endoscopic biopsy specimens neoadjuvant treatment pathological complete response surgical specimen neoadjuvant radiochemotherapy plus radical resection group ; 4 . Assess impact definitive radiochemotherapy versus neoadjuvant radiochemotherapy plus radical resection quality life patient . Clinical Complete Response After Neoadjuvant Treatment : Endoscope biopsy pathologic diagnosis indicate pathologic complete response Neoadjuvant treatment ; upper gastrointestinal/chest CT symptom assessment indicate clinical complete response Neoadjuvant treatment ( Concurrent Radiochemotherapy : Radiotherapy , Intensity Modulation Radiation Therapy ( IMRT ) , 40Gy ; Chemotherapy , Docetaxel （25mg/m2）+Cisplatin ( 25mg/m2 ) , 1st/8th/15th/22nd day</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Thoracic esophageal cancer patient esophagocardial cancer patient , locally advance resectable tumor , clinically identify treatment T13N+M0 accord UICC ( International Union Against Cancer ) TNM ( primary tumor , regional node , metastasis ) Classification Malignant Tumours , 7th ed . 2 . Untreated patient receive antitumor therapy 3 . Life expectancy &gt; 6 month 4 . Age : 1870 year 5 . White blood cell count ≥4.0×109/l , ANC ( absolute neutrophil count ) ≥1.5×109/l , thrombocyte count ≥1011/l , hemoglobin ≥90 g/l ; normal liver kidney function 6. WHO PS ( Performance Status ) : 01 7 . Patients understood study give sign informed consent 1 . Patients already receive antitumor therapy , include chemotherapy , radiotherapy surgery ; 2 . Patients hemorrhage complicate hemorrhage 3 . Other uncontrollable patient suitable surgery 4 . Pregnant lactate woman 5 . Patients agree without acknowledgement result psychological , family social factor 6 . Patients CTCAE ( Common Terminology Criteria Adverse Events Version 4.0 ) grade ≥2 peripheral neuropathy 7 . Patients ever malignant tumor esophageal cancer 8 . Patients history diabetes &gt; 10 year unsatisfactory control blood glucose level 9 . Patients serious heart , lung , liver kidney dysfunction , hematopathy , immune system disease cachexia therefore tolerate chemotherapy surgery 10 . Others .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>